Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. News
  7. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-09-30 am EDT
38.05 HKD   -0.13%
09/20RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
AQ
09/19RemeGen Completes Third Phase of Clinical Study For Lupus Treatment In China
MT
09/19RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirmatory Study to Treat Systemic Lupus Erythematosus in China
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RemeGen to Purchase $4.4 Million of Wealth Management Products

08/03/2022 | 03:27am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
HKG LIMITED -3.41% 17 End-of-day quote.-11.30%
REMEGEN CO., LTD. -0.13% 38.05 Delayed Quote.-51.16%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) 0.65% 7.1365 Delayed Quote.12.27%
All news about REMEGEN CO., LTD.
09/20RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept f..
AQ
09/19RemeGen Completes Third Phase of Clinical Study For Lupus Treatment In China
MT
09/19RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirm..
CI
09/19RemeGen Co., Ltd.(XSSC:688331) added to S&P Global BMI Index
CI
09/02UBS Adjusts RemeGen's Price Target to HK$75.20 From HK$75.03, Keeps at Buy
MT
08/31Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO
MT
08/30RemeGen Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/19Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO
MT
08/03RemeGen to Purchase $4.4 Million of Wealth Management Products
MT
07/22RemeGen to Purchase Wealth Management Products from Qingdao Bank for $11.8 Million
MT
More news
Analyst Recommendations on REMEGEN CO., LTD.
More recommendations
Financials
Sales 2022 932 M 131 M 131 M
Net income 2022 -942 M -132 M -132 M
Net cash 2022 2 509 M 353 M 353 M
P/E ratio 2022 -19,3x
Yield 2022 -
Capitalization 25 051 M 3 521 M 3 521 M
EV / Sales 2022 24,2x
EV / Sales 2023 11,1x
Nbr of Employees 2 500
Free-Float 50,5%
Chart REMEGEN CO., LTD.
Duration : Period :
RemeGen Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REMEGEN CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 34,48 CNY
Average target price 62,93 CNY
Spread / Average Target 82,5%
EPS Revisions
Managers and Directors
Jian Min Fang CEO, Executive Director & Chief Scientific Officer
Dao Tian Fu President
Jia Li Chief Financial Officer & Joint Secretary
Weidong Wang Chairman
Ruyi He Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REMEGEN CO., LTD.-51.16%3 521
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044